SCHEMBL3398891

SCHEMBL3398891

CN(C)NC(=O)c1cccc(-c2ccc(/C=C3/SC(=S)NC3=O)o2)c1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 6/20 0.73
HSPD1 P10809 1/20 0.59
HSPE1 P61604 1/20 0.59
GSK3A P49840 4/20 0.58
GSK3B P49841 4/20 0.58
INSR P06213 3/20 0.58
IGF1R P08069 3/20 0.58
PIK3CA P42336 1/20 0.53
PTP4A3 O75365 1/20 0.51
RXRA P19793 2/20 0.50
MEN1 O00255 1/20 0.49
CASP3 P42574 1/20 0.49
BLM P54132 1/20 0.49
KMT2A Q03164 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12990200 1.00 PIK3CG (0.73) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3398896 1.00 PIK3CG (0.73) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3363249 0.86 PIK3CG (0.73) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL12990003 0.86 PIK3CG (0.73) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3363244 0.86 PIK3CG (0.73) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL12990070 0.85 PIK3CG (0.83) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3366741 0.85 PIK3CG (0.83) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3366739 0.85 PIK3CG (0.83) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3364888 0.85 PIK3CG (1.00) PIK3CGHSPD1HSPE1GSK3AGSK3B
SCHEMBL3364886 0.85 PIK3CG (1.00) PIK3CGHSPD1HSPE1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIK3CG 456/4885HSPD1 1307/4885HSPE1 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.